97 related articles for article (PubMed ID: 14984966)
1. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.
Wadler S; Levy D; Frederickson HL; Falkson CI; Wang Y; Weller E; Burk R; Ho G; Kadish AS;
Gynecol Oncol; 2004 Mar; 92(3):957-64. PubMed ID: 14984966
[TBL] [Abstract][Full Text] [Related]
2. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
3. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
4. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
5. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix.
Song SH; Lee JK; Seok OS; Saw HS
Gynecol Oncol; 2007 Mar; 104(3):732-8. PubMed ID: 17188341
[TBL] [Abstract][Full Text] [Related]
6. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients.
Silins I; Avall-Lundqvist E; Tadesse A; Jansen KU; Stendahl U; Lenner P; Zumbach K; Pawlita M; Dillner J; Frankendal B
Gynecol Oncol; 2002 May; 85(2):333-8. PubMed ID: 11972397
[TBL] [Abstract][Full Text] [Related]
8. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients.
de Boer MA; Jordanova ES; Kenter GG; Peters AA; Corver WE; Trimbos JB; Fleuren GJ
Clin Cancer Res; 2007 Jan; 13(1):132-8. PubMed ID: 17200347
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
10. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
[TBL] [Abstract][Full Text] [Related]
11. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.
Warrino DE; Olson WC; Knapp WT; Scarrow MI; D'Ambrosio-Brennan LJ; Guido RS; Edwards RP; Kast WM; Storkus WJ
Clin Cancer Res; 2004 May; 10(10):3301-8. PubMed ID: 15161683
[TBL] [Abstract][Full Text] [Related]
12. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
13. IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response.
Lee KA; Cho KJ; Kim SH; Shim JH; Lim JS; Cho DH; Song MS; Dinarello CA; Yoon DY
Cancer Lett; 2005 Nov; 229(2):261-70. PubMed ID: 16125299
[TBL] [Abstract][Full Text] [Related]
14. The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer.
Fisher SG; Benitez-Bribiesca L; Nindl I; Stockfleth E; Muller M; Wolf H; Perez-Garcia F; Guzman-Gaona J; Gutierrez-Delgado F; Irvin W; Gissmann L
Gynecol Oncol; 1996 Apr; 61(1):73-8. PubMed ID: 8626121
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
[TBL] [Abstract][Full Text] [Related]
16. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
Valdespino V; Gorodezky C; Ortiz V; Kaufmann AM; Roman-Basaure E; Vazquez A; Berumen J
Gynecol Oncol; 2005 Jan; 96(1):92-102. PubMed ID: 15589586
[TBL] [Abstract][Full Text] [Related]
17. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
Lee DW; Anderson ME; Wu S; Lee JH
Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
[TBL] [Abstract][Full Text] [Related]
18. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
Jin HS; Park EK; Lee JM; NamKoong SE; Kim DG; Lee YJ; Jun HJ; Han BD; Bae SM; Ahn WS
Gynecol Oncol; 2005 May; 97(2):559-67. PubMed ID: 15863160
[TBL] [Abstract][Full Text] [Related]
19. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
20. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
